Vaccines Market by Type (Monovalent Vaccine, Multivalent Vaccine), Technology Type (Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA (mRNA) Vaccines), Indication, Route of administration, Age Group - Global Forecast 2024-2030

360iResearch Analyst
Want to know more about the vaccines market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[194 Pages Report] The Vaccines Market size was estimated at USD 55.66 billion in 2023 and expected to reach USD 59.94 billion in 2024, at a CAGR 7.79% to reach USD 94.14 billion by 2030.

Vaccines Market
To learn more about this report, request a free PDF copy

Vaccines are biological preparations that equip the body's immune system with the capability to combat disease-causing microbes effectively. They work by stimulating the immune response to generate a specific defense mechanism, predominantly in the form of antibodies, against harmful pathogens. The rising incidence of infectious diseases globally and the rise in immunization programs worldwide significantly influence this growth. Moreover, favorable government initiatives and policies for vaccine development are also driving market growth. High development costs, lengthy testing and approval process issues over product recalls, and inaccessibility in a few regions pose challenges to the growth of the vaccine market. Integration of adjuvants in vaccines, development of therapeutic vaccines, and growth in the contract manufacturing of the vaccines are expected to create significant growth opportunities in the market.

Vaccines Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Type: Significant preference for monovalent vaccines for specific disease prevention

Monovalent vaccines target one antigen or microorganism, producing a potent, focused immune response. For instance, the measles vaccine, commonly delivered in the M-M-R II format, is a globally prevalent monovalent vaccine. Such vaccines are ideal when single diseases dominate, requiring a specific immune response. Multivalent vaccines stimulate immunity against multiple pathogens or strains of the same pathogen. A widespread multivalent vaccine is the DTP vaccine, which safeguards against Diphtheria, Tetanus, and Pertussis. Multivalent vaccines are best suited for environments with multiple concurrent diseases. Even though monovalent vaccines excel in combating specific illnesses and multivalent vaccines offer broad-scope protection, both types are indispensable for addressing global disease prevention needs. Crafting multivalent vaccines requires a more intricate process to ensure efficacy against various pathogens. Nevertheless, their vast coverage could present superior, cost-effective advantages from a public health standpoint.

Technology Type: Rising development in the conjugate vaccines as an viable alternative

Inactivated vaccines, typically prescribed for the immune-compromised, are produced by neutralizing a pathogen. Live-attenuated vaccines, developed from a live yet weakened virus, provide prolonged immunity suitable for robust immune systems. Messenger RNA (mRNA) vaccines, a new breed of vaccines, use a copy of a part of the virus's RNA to provoke an immune response. Subunit, recombinant, polysaccharide, and conjugate vaccines are made from a piece of the pathogen that can be utilized by those allergic to certain vaccine components. Toxoid vaccines are designed to protect against bacteria-produced toxins, and are provided to individuals prone to such infections. Viral vector vaccines function by carrying a piece of DNA that codes for a protein found on the virus surface to stimulate an immune response. Each of these types of vaccines plays a crucial role in preventing infectious diseases. The selection depends mainly on the patient's age, immune status, or predisposed allergies. New developments, collaborations, and launches have further enriched this field, providing better patient care options.

Indication: Growing need for DPT vaccine for protection against serious respiratory ailments

The DPT vaccine is administered to protect against diphtheria, pertussis (whooping cough), and tetanus. It's typically given in a series of five shots to infants and toddlers at two months, four months, six months, 15-18 months, and 4-6 years of age to develop immunity. Hepatitis vaccines, including Hepatitis A and B, are administered to prevent these viral infections that primarily affect the liver. Both vaccines are usually given as two shots, with the second dose delivered six months after the first. The Human Papillomavirus (HPV) vaccine is given to protect against the viral infection known to cause certain types of cancers, such as cervical and throat cancer. It is usually given to preadolescents aged 9-14 over two doses six months apart. The influenza vaccine, typically known as the 'flu shot,' is given annually to protect against seasonal flu viruses. It's recommended for everyone over the age of 6 months, particularly those at risk of severe flu complications, such as the elderly and people with chronic health conditions/ The Measles vaccine is commonly given as part of the measles, mumps, and rubella (MMR) vaccine, and administered in a series of two doses at 12-15 months and 4-6 years of age to protect against these highly contagious viral diseases. The Meningococcal vaccine is given to protect against bacterial infections that can lead to severe conditions such as meningitis and bloodstream infections. It's usually administered to preteens and teenagers and includes a booster shot in the late teens. Mumps and Rubella vaccines are typically given as part of the MMR vaccine and measles. Two doses are given in childhood to ensure immunity. However, adults without immunity or vaccination records may also require vaccination. The Pneumococcal vaccine protects against types of bacteria that cause pneumococcal disease, including pneumonia, meningitis, and bloodstream infections, for all children under the age of 2, adults 65 years and above, and individuals with specific health conditions. The Polio vaccine is given to prevent poliomyelitis, a highly infectious disease that leads to paralysis. Children typically receive four doses at two months, four months, 6-18 months, and 4-6 years. The Rotavirus vaccine protects against a viral infection provoking severe diarrhea in infants and young children. It's typically given orally in two or three doses during the first six months of life. The Varicella vaccine is administered to protect against chickenpox, a highly contagious disease. It's typically given in two doses, with the first dose at 12-15 months and the second at 4-6 years of age.

Route of administration: Increasing adoption of oral vaccines for longer-lasting immune responses

Intramuscular and Subcutaneous administrations are the most common methods for vaccine delivery. This route allows the vaccine to be retained in the muscle or beneath the skin, promoting an efficient immune response. The oral route of vaccine administration is a popular alternative often used when needle-based administration is not preferred or practical. Oral vaccines, such as those for rotavirus, polio (OPV), and cholera, have proven effective and easy to administer. Both administration routes have unique advantages, such as swift immunity in intramuscular and subcutaneous administration and needle-free convenience with oral vaccines. However, they each have drawbacks, such as pain and needle-stick injuries from intramuscular and subcutaneous injections or restrictions due to gastrointestinal conditions for oral vaccines. Vaccine selection depends upon the individual vaccine, recipient, and healthcare environment. Advancements in non-intrusive vaccination methods are anticipated to drive industry research and partnerships.

Age Group: wider adoption of pediatric vaccine as a preventive measure owing to rising HPV vaccine usability

The adult population, considered those over the age of 18, comprises the more significant portion of the vaccine market. This group primarily requires vaccines to boost their immunity, prevent diseases, and meet the needs of travel vaccinations. The pediatric segment of the vaccine market focuses on children under the age of 18. Necessary immunizations, disease prevention, and peak medical advisory compliance primarily drive this category. While the adult vaccine market excels in prevention and maintenance, the pediatric section is fundamentally preventive.

Regional Insights

In Asia-Pacific, robust economies such as China, India, and Japan have exhibited significant growth in vaccine markets due to large population densities and high prevalence of infectious diseases, necessitating comprehensive immunization drives. There's a high need for vaccines in the Americas, comprising countries such as the United States and Canada, owing to the demographic makeup and an expansive public health infrastructure. Significant investments in research and development (R&D) of vaccines, recent patents, and initiatives further fuel the growth. The EMEA region, with diverse economic landscapes, displays varying consumer behavior. The European Union, with well-funded health systems, necessitates extensive immunization programs. The Middle East and Africa possess a significant potential for market growth. Initiatives such as the collaboration between the Serum Institute of India and the Africa Vaccine Acquisition Trust in 2022 to supply COVID-19 vaccines are pivotal changes reshaping this landscape.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Oxford R21/Matrix-M Malaria Vaccine Receives WHO Recommendation for Use

    The R21/Matrix-M malaria vaccine, developed by the University of Oxford with the Serum Institute of India with Novavax's adjuvant technology, has received a recommendation for use by the World Health Organization (WHO) based on its adherence to safety, quality, and effectiveness standards. The vaccine has been licensed for use in Ghana, Nigeria, and Burkina Faso. [Published On: 2023-10-02]

  • BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission

    BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) formed a strategic partnership to develop mRNA-based vaccine candidates, such as BNT166, with the goal of preventing the occurrence of Mpox. In support of their 100 Days Initiative Mission, CEPI has committed up to USD 90 million in funding to this project, which aims to safeguard against future pandemics. The BNT166 vaccine candidate is expected to serve as a safe and scalable prophylactic against Mpox, while also generating valuable data for the rapid development of vaccines targeting Orthopoxviruses. This partnership between BioNTech and CEPI is dedicated to ensuring equitable access to any licensed vaccines resulting from this initiative at an affordable price in lower-income countries. [Published On: 2023-09-18]

  • Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

    Pfizer Inc. and BioNTech SE received the U.S. Food and Drug Administration (FDA) approval for emergency use authorization for their COVID-19 vaccine. This (COMIRNATY 2023-2024 Formulation) authorization includes individuals 12 years and older, with additional authorization for individuals 6 months to 11 years of age. The vaccine is recommended as a single dose for most individuals aged 5 years and older. This updated vaccine aims to provide improved protection against symptomatic and severe disease. [Published On: 2023-09-11]

Key Company Profiles

The report delves into recent significant developments in the Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co.,Ltd., CSL Limited, CureVac SE, Daiichi Sankyo Co., Ltd., Emergent BioSolutions Inc., Gennova Biopharmaceuticals Limited, GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Mitsubishi Chemical Group Corporation, Moderna Inc., Novavax, Inc., Pfizer Inc., Sanofi Group, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Monovalent Vaccine
    • Multivalent Vaccine
  • Technology Type
    • Inactivated Vaccines
    • Live-Attenuated Vaccines
    • Messenger RNA (mRNA) Vaccines
    • Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
    • Toxoid Vaccines
    • Viral Vector Vaccines
  • Indication
    • DPT
    • Hepatitis
    • Human Papillomavirus
    • Influenza
    • Measles
    • Meningococcal Disease
    • Mumps & Rubella
    • Pneumococcal Disease
    • Polio
    • Rotavirus
    • Varicella
  • Route of administration
    • Intramuscular & Subcutaneous
    • Oral
  • Age Group
    • Adults
    • Pediatric

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Vaccines Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaccines Market?
  3. What are the technology trends and regulatory frameworks in the Vaccines Market?
  4. What is the market share of the leading vendors in the Vaccines Market?
  5. Which modes and strategic moves are suitable for entering the Vaccines Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Vaccines Market, by Type
  7. Vaccines Market, by Technology Type
  8. Vaccines Market, by Indication
  9. Vaccines Market, by Route of administration
  10. Vaccines Market, by Age Group
  11. Americas Vaccines Market
  12. Asia-Pacific Vaccines Market
  13. Europe, Middle East & Africa Vaccines Market
  14. Competitive Landscape
  15. Competitive Portfolio
  16. List of Figures [Total: 26]
  17. List of Tables [Total: 482]
  18. List of Companies Mentioned [Total: 25]
How Adjuvants are Changing the Game in Vaccine Development
December 1, 2023
How Adjuvants are Changing the Game in Vaccine Development
Vaccines have been a critical part of modern medicine, transforming the healthcare ecosystem. Protecting against viral, bacterial, or fungal infections is essential to prevent epidemics and outbreaks. Historically, vaccines have been developed based on attenuated or dead pathogens that are effective against the disease. However, the emergence of resistant strains and the need to protect against new strains has pushed vaccine developers to explore new strategies. Integration of adjuvants in vaccines and therapeutic vaccines have emerged as some of the most promising strategies currently being investigated.

Adjuvants are substances added to vaccines to enhance their efficacy and stimulate the immune system. They work by improving the immune response, boosting the body's ability to recognize and respond to the vaccine. Some of the most commonly used adjuvants include alum, oil-in-water emulsions, liposomes, and virosomes. While adjuvants have been in use for several decades, their integration into vaccines has gained renewed interest in recent years due to the need for more effective vaccines.

Therapeutic vaccines involve using vaccines to treat patients with existing medical conditions. They work by amplifying the immune response against specific antigens associated with the disease. Unlike preventive vaccines, therapeutic vaccines aim not to prevent infections but to treat existing conditions by triggering the body's immune system to fight the disease.

One of the most exciting developments in vaccine development is integrating personalized medicine and adjuvants. This approach involves tailoring the vaccine to the individual's unique genetic makeup and immune system. By doing so, it is possible to develop vaccines that are more targeted, effective, and safer than traditional vaccines. Personalized medicine and adjuvants are currently being explored in cancer treatment, showing promising results in treating patients with advanced cancers that have not responded to other treatments.

Overall, integrating adjuvants in vaccines and developing therapeutic vaccines are promising strategies that are changing the game in vaccine development. As we continue to fight against infectious diseases, exploring new and innovative approaches to develop effective vaccines is essential. Integrating adjuvants and personalized medicine opens new avenues for developing effective and targeted vaccines that are tailor-made to individual patients' needs. With ongoing research and development, the future of vaccine development looks bright, and it offers hope for a healthier tomorrow.

Frequently Asked Questions
  1. How big is the Vaccines Market?
    Ans. The Global Vaccines Market size was estimated at USD 55.66 billion in 2023 and expected to reach USD 59.94 billion in 2024.
  2. What is the Vaccines Market growth?
    Ans. The Global Vaccines Market to grow USD 94.14 billion by 2030, at a CAGR of 7.79%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.